Business
InspireMD Announces Fourth Quarter and Year-End 2019 Financial Results
Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10,
About this update from Inspiremd Inc.
[{"type":"text","content":"Robust CGuard™ EPS year-over-year revenue growth of 31%\n Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the fourth quarter and year ended December 31, 2019. Fourth Quarter 2019 and recent highlights: Announced the appointment of leading medical devices executive Marvin Slosman as Chief Executive OfficerGenerated revenue of $1,013,000, representing growth of 23% over the fourth quarter 2018, driven by continued strong growth in sales of CGuard™ EPSGenerated CGuard™ EPS revenue of $921,000, up 31% over the fourth quarter 2018Chosen for the third consecutive year to demonstrate a successful live clinical case transmission featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020 that showcased CGuard’s ease-of-use and exceptional patient safety featuresPresented updated data at the 2019 VEITH Symposium and LINC 2020 from the IRONGUARD 2 study, a physician initiated prospective multi-center and multi-specialty registry that enrolled more than 700 patients, which suggested that the use of the CGuard EPS in routine clinical practice is associated with no major periprocedural and 30-day neurologic complicationsBegan exploring the potential broadening of the company’s product portfolio with procedural protection devices based on its reverse flow technologyBeginning to engage with French health authorities to gain reimbursement in FranceAdvanced productive discussions with FDA and addressed requests related to the company’s pending IDE application “I assumed the role of Chief Executive Officer of InspireMD because I believe the combination of the substantial amount of published data confirming the safety and efficacy of CGuard, along with real world performance demonstrating the unique patient safety features of the device and a growing appreciation of CAS, or carotid artery stenting, as a first line treatment for CAD, position CGuard EPS and MicroNet to change the standard of care in this disease,” said Marvin Slosman, Chief Executive Officer. “The strong revenue growth that we reported in the fourth quarter was ag...